Fig. 2: DNA ploidy and PTEN measurement results at each procedure, presented separately for treated and not treated patients. | British Journal of Cancer

Fig. 2: DNA ploidy and PTEN measurement results at each procedure, presented separately for treated and not treated patients.

From: DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance

Fig. 2

Among the 558 patients included in the study, 230 underwent treatment during the follow-up period, while 328 received no treatment. At the diagnostic procedure, 73 treated patients and 52 untreated patients were measured to have DNA ploidy and/or PTEN “aberrant” (DPP-aberrant) tumours (depicted by red bars). At the first surveillance procedure, DPP-aberrant tumours were observed in 44 treated patients and 19 untreated patients that did not demonstrate this characteristic at the previous procedure. Of the 44 treated patients with DPP-aberrant tumours in the first surveillance procedure, 26 also experienced disease reclassification based on standard clinicopathological parameters at that time (depicted by yellow bars). This is illustrated for all procedures. In total, DPP-aberrant tumours were observed in 140 (73 + 18 + 26 + 5 + 14 + 1 + 3) of the 226 treated patients (62%), and in 81 (52 + 19 + 6 + 2 + 2) of the 269 untreated patients (30%) with valid measurements. Among the treated patients, DPP-aberrant tumours were detected before disease reclassification in 97 (73 + 18 + 5 + 1) patients and at the time of disease reclassification in 43 (26 + 14 + 3) patients. DPP-normal DNA ploidy and PTEN “normal”, DPP-aberrant DNA ploidy and/or PTEN “aberrant”.

Back to article page